Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 5, 2002, Pages 398-404

  Bauer, Kenneth A ^a   Eriksson, Bengt I ^b   Lassen, Michael R ^c   Turpie, Alexander G G ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Hoersholm Hospital   (Denmark)

^d HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] 5 [(2' AMINOSULFONYL 1,1' BIPHENYL 4 YL)CARBAMOYL] 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; 3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; 4 [(2 AMIDINO 1,2,3,4 TETRAHYDRO 7 ISOQUINOLINYLOXY)METHYL] 1 (4 PYRIDINYL) 4 PIPERIDINECARBOXYLIC ACID; ACETYLSALICYLIC ACID; ANTISTASIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DIGOXIN; ENOXAPARIN; FONDAPARINUX; FXV 673; LOW MOLECULAR WEIGHT HEPARIN; M 55113; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; PIROXICAM; RPR 130737; RPR 208566; UNCLASSIFIED DRUG; WARFARIN; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID METHANESULFONATE;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HIP FRACTURE; HUMAN; INCIDENCE; KNEE SURGERY; LUNG EMBOLISM; NONHUMAN; ORTHOPEDIC SURGERY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME;

EID: 0036329373     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200209000-00010     Document Type: Review

References (58)

1. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study
2. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
3. Heparin and low-molecular-weight heparin: Mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
4. New anticoagulant drugs
5. SR 90107A/Org 31540, a novel anti-factor Xa antihrombotic agent
6. Overview of the clinical results of pentasaccharide in major orthopedic surgery
7. The role in cardiology of the first synthetic factor Xa inhibitor: Lessons from the results of the clinical program in venous thromboembolism
8. A synthetic factor-Xa inhibitor (ORG31540/SR90107A) as an adjunct to fibrinolysis in acute myocardial infraction. The PENTALYSE study
9. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
10. Comparative mechanism of action and pharmacokinetics of pentasaccharide and LMW heparins
11. Pharmacokinetics of Org31540/SR90107a in young and elderly healthy subjects: A highly favorable pharmacokinetic profile
12. In vitro protein binding of Org31540/R90107a in human plasma and purified antithrombin III
13. Lack of pharmacokinetic (PK) and pharmacodynamic (PD) interaction between the first synthetic factor Xa inhibitor and warfarin in human volunteers
14. Safety and pharmacokinetics (PK) of co-administration of the first synthetic factor Xa inhibitor and aspirin in human volunteers
15. Interaction of fondaparinux sodium with acetylsalicylic acid (ASA) and piroxicam in healthy male volunteers
16. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers
17. Absence of placental transfer of pentasaccharide (fondaparinux, Arixtra®) in the dually perfused human cotyledon in vitro
18. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomized double-blind trial
19. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
20. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery
21. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in elective hip replacement surgery. A randomized double-blind comparison
22. Pentasaccharide (fondaparinux, Arixtra®) versus enoxaparin for the prevention of venous thromboembolism (VTE) in major orthopedic surgery: Subgroup analyses on efficacy
23. Fondaparinux sodium is superior to enoxaparin for the prevention of venous thromboembolism in major surgery irrespective of patients and surgery characteristics
24. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity
25. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-hour patency after coronary fibrinolysis in dogs
26. In vitro characterization of a novel factor Xa inhibitor, RPR 130737
27. Pharmacological characterization of a novel factor Xa inhibitor, FXV673
28. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals
29. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis
30. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants
31. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers
32. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor
33. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2′-(methylsulfonyl)-[1,1′- biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
34. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis
35. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
36. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice
37. Nonpeptide factor Xa inhibitors II. Anti-thrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis
38. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics
39. Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa
40. NMR solution structure of the recombinant tick anticoagulant protein (rTAP), a factor Xa inhibitor from the tick Ornithodoros moubata
41. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation
42. Isolation, sequence analysis, and cloning of haemadin. An anticoagulant peptide from the Indian leech
43. Isolation and characterization of hirustasin, an antistasin-type serine-proteinase inhibitor from the medical leech Hirudo medicinalis
44. Mutational analysis of antistasin, an inhibitor of blood coagulation factor Xa derived from the Mexican leech Haementeria officinalis
45. Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: Comparison with heparin and hirudin in a rabbit thrombosis model
46. A new factor Xa inhibitor (lefaxin) from the Haementeria depressa leech
47. Therostasin, a novel clotting factor Xa inhibitor from the rhynchobdellid leech, Theromyzon tessulatum
48. Cloning, purification, crystallization and preliminary X-ray diffraction analysis of the antistasin-type inhibitor ghilanten (domain I) from Haementeria ghilianii in complex with porcine beta-trypsin
49. Structural and functional characterization of tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation factor Xa
50. Savignin, a potent thrombin inhibitor isolated from the salivary glands of the tick Ornithodoros savignyi (Acari: Argasidae)
51. Isolation and characterization of americanin, a specific inhibitor of thrombin, from the salivary glands of the lone star tick Amblyomma americanum (L.)
52. Purification and characterization of an anticoagulant from the salivary glands of the ixodid tick Rhipicephalus appendiculatus
53. Isolation and characterization of an anticoagulant present in the salivary glands of the bont-legged tick, Hyalomma truncatum
54. Factor Xa (FXa) inhibitor from the nymphs of the camel tick Hyalomma dromedarii
55. Ancylostoma caninum anticoagulant peptide: A hookworm-derived inhibitor of human coagulation factor Xa
56. Adis New Drug Profile. Fondaparinux sodium
57. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin associated thrombocytopenia
58. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia